Fidelis Capital Partners LLC Acquires 1,560 Shares of AbbVie Inc. (NYSE:ABBV)

Fidelis Capital Partners LLC lifted its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 5.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 28,519 shares of the company's stock after purchasing an additional 1,560 shares during the period. Fidelis Capital Partners LLC's holdings in AbbVie were worth $5,975,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in ABBV. EnRich Financial Partners LLC increased its position in shares of AbbVie by 196.4% during the fourth quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock valued at $29,000 after buying an additional 110 shares during the period. Abound Financial LLC purchased a new position in shares of AbbVie during the first quarter worth about $30,000. Prudent Man Investment Management Inc. purchased a new position in shares of AbbVie during the fourth quarter worth about $32,000. Siemens Fonds Invest GmbH grew its holdings in shares of AbbVie by 197.6% during the fourth quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company's stock worth $32,000 after purchasing an additional 119,141 shares in the last quarter. Finally, Pinney & Scofield Inc. purchased a new stake in AbbVie in the fourth quarter worth approximately $36,000. 70.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several research reports. BNP Paribas raised AbbVie to a "hold" rating in a research note on Thursday, May 8th. Guggenheim upped their target price on AbbVie from $214.00 to $216.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Citigroup boosted their price objective on AbbVie to $205.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Bank of America boosted their price objective on AbbVie to $204.00 and gave the company a "hold" rating in a research report on Monday, June 9th. Finally, Evercore ISI boosted their price objective on AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a research report on Monday, April 28th. Eight research analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, AbbVie presently has an average rating of "Moderate Buy" and a consensus price target of $211.29.

AbbVie Stock Performance

Shares of ABBV stock traded down $2.68 during trading hours on Friday, reaching $192.32. 4,990,162 shares of the company traded hands, compared to its average volume of 6,311,659. AbbVie Inc. has a 12-month low of $163.81 and a 12-month high of $218.66. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.76 and a quick ratio of 0.64. The company has a market cap of $339.71 billion, a P/E ratio of 81.84, a P/E/G ratio of 1.28 and a beta of 0.48. The firm has a 50-day moving average price of $187.01 and a 200 day moving average price of $189.05.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Friday, April 25th. The company reported $2.46 earnings per share for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The firm had revenue of $13.34 billion for the quarter, compared to analysts' expectations of $12.91 billion. During the same period in the previous year, the firm earned $2.31 EPS. The business's quarterly revenue was up 8.4% on a year-over-year basis. As a group, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 3.41%. The ex-dividend date is Tuesday, July 15th. AbbVie's dividend payout ratio (DPR) is presently 279.15%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.